|
|
Commercial Insight: Antidyslipidemics - Statins Hit the Brakes on Market GrowthPublished by: Datamonitor Published: Dec. 23, 2005 - 181 Pages Table of ContentsTABLE OF CONTENTS About the Cardiovascular pharmaceutical analysis team 3 CHAPTER 1 EXECUTIVE SUMMARY 4 Objective of the analysis 4 Datamonitor insight into the dyslipidemia market 5 CHAPTER 2 MARKET DEFINITION AND OVERVIEW 12 Market definition for this report 12 Current market situation 12 National markets 14 The statin market 17 Lipitor - the global market leader 19 Crestor - fastest-growing statin 19 Combination therapy 22 Vytorin 23 The fibrate market 25 TriCor/Lypanthyl (fenofibrate) 27 The cholesterol uptake inhibitor market 28 Zetia 28 The nicotinic acid derivatives 30 Niaspan 31 The ion exchange resins 32 The other antidyslipidemics market 32 Omega-3 oils 33 Probucol, Benflourex and Colesevelam 33 CHAPTER 3 COUNTRY MARKET ASSESSMENTS 34 Current and future opportunities and threats in the antidyslipidemic market 34 Global opportunities and threats 34 Threats 42 US: opportunities and threats 49 Market overview 49 Japan: opportunities and threats 59 Market overview 59 France: opportunities and threats 71 Market overview 71 Germany: opportunities and threats 77 Market overview 77 Italy: opportunities and threats 84 Market overview 84 Spain: opportunities and threats 90 Market overview 90 UK: opportunities and threats 96 Market overview 96 Summary of environmental issues affecting the antidyslipidemic market size 102 CHAPTER 4 FORECAST ANALYSIS 103 Assumptions and events 103 Trial results 104 New product launches 105 Atorvastatin + torcetrapib 105 Livalo 105 Forecasts 106 CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES 107 Pfizer’s franchise rotation strategies: a means of protecting brand revenue 107 Lipitor: Pfizer’s biggest success 107 Lipitor: sales are forecast to plummet in the next decade 108 Atorvastatin + torcetrapib: will this FDC be Pfizer’s next blockbuster? 109 Caduet (atorvastatin + amlodipine): a winning combination? 111 Implications of two recent trials 115 IDEAL TRIAL: implications 115 Japanese MEGA trial 116 APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS 119 Statin market data 119 Lipitor 119 Zocor 120 Pravachol 121 Crestor 122 Vytorin 123 Fibrate market data 124 Lipanthyl/Tricor 124 Cedur/Bezatol 125 Cholesterol uptake inhibitors 126 Zetia 126 Nicotinic acid derivatives 127 Niaspan 127 Ion exchange resins 128 Questran 128 Other antidyslipidemics 129 WelChol 129 APPENDIX B 130 Bibliography 130 Epidemiology 130 Clinical trial data 131 Datamonitor 133 Other research articles 133 Press releases 133 Websites 134 Report methodology 134 Japan sales data 134 Key opinion leaders 134 APPENDIX C - MARKET FORECAST DATA 136 US forecasts 136 Japan forecasts 139 France forecasts 142 Germany forecasts 145 Italy forecasts 148 Spain forecasts 151 UK forecasts 154 M5EU forecasts 157 Global forecasts 160 About Datamonitor 165 About Datamonitor Healthcare 165 About the Cardiovascular analysis team 166 Disclaimer 167 AbstractIntroductionThe antidyslipidemics market is driven by the statins, which account for 87% of it. However, as many statins are expected to face patent expiry in the coming decade their role is expected to change from a driver to that of almost a resistor. Manufacturers are looking to novel products to protect their franchise, such as Pfizer's atorvastatin/torcetrapib. Scope Country specific event-driven sales forecasts for the period 2005-14 for the US, Japan, France, Germany, Italy, Spain and the UK and Global overview Patient potential and prescribing trends overview in the antidyslipidemics market, based on historical sales data and future key events Profiles of the country and market-specific issues which will impact future sales, including generic erosion and class switching Case studies presenting Pfizer's strategy with atorvastatin/torcetrapib to maintain the Lipitor franchise, and the impact of key clinical trials Highlights Increased knowledge of the metabolic syndrome, fears of statin side effects, and the increasing data on the importance of HDL have all served to drive growth of the adjunctive anti-dyslipidemic agent market, by creating an opportunity for novel as well as combination therapies. Pfizer's atorvastatin + torcetrapib combination is expected to have a major impact on the dyslipidemia market and is expected to compete with both atorvastatin and Vytorin (simvastatin + ezetimibe). While AstraZeneca's Crestor is set to significantly increase in sales due to new safety data. The expiration of key statin patents could lead to the shrinking of the market value. The situation will be salvaged by the growing classes of cholesterol uptake inhibitors and single pill combinations. Reasons to Purchase View independent, event-driven forecasts for key anti-dyslipidemic products and classes across the seven major markets Obtain key opinion leader comments on various topics including prescribing trends and opinions on currently marketed and late stage development drugs Identify the potential impact of clinical trial results, EU healthcare reform and new product launches on the antidyslipidemic market Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||